Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies

This study is testing a new type of cell therapy called CAR-NK (using natural killer cells engineered to target a protein called CD5) in people with relapsed or refractory T-cell leukemia or T-cell lymphoma — cancers that are difficult to treat and have come back or stopped responding to standard treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have a confirmed diagnosis of T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoma - Your cancer has relapsed (come back) or is refractory (not responding) after multiple prior treatments - For T-ALL: your cancer came back within 12 months of achieving remission, failed standard induction, or relapsed after a stem cell transplant **You may NOT be eligible if...** - You have not yet tried standard treatments - Your cancer does not express the CD5 protein target - You have serious organ dysfunction that would make the treatment unsafe Talk to your doctor to see if this trial is right for you.